anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The incidence of proximal humerus fractures continues to increase and is among one of the more common fractures seen in the adult population. Proximal humerus fracture dislocations, however, are less common. Despite the decreased prevalence, fracture dislocations have unique challenges with respect to obtaining an anatomical reduction and more frequently involve an open surgical reduction. In addition, depending on other fracture characteristics, there are various treatment options for the fracture itself. While fracture dislocations ultimately lead to increased AVN and revision surgery, further discussion surrounding the direction of dislocation and how it may influence overall outcomes has not been addressed in the previous literature. The study design utilizes a retrospective cohort from the last ten years, by asking patients who have had a previously surgically treated proximal humerus fracture dislocations to come back to the surgeon's private clinic to complete a single visit assessment. During this assessment the consenting participant will receive x-rays and complete patient reported outcome measures. In conjunction, these will be utilized to assess overall function and the existence of avascular necrosis.
Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of sham tDCS. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds at the beginning of the sham condition before being extinguished over the course of seconds. Individuals randomized into the sham arm will be offered the option to crossover to real tDCS after their participation is complete.
INTRODUCTION: Patients with squamous cell carcinoma of the head and neck (HNSCC) often receive post-operative radiotherapy (RT). A package time between surgery and completion of RT of ≤100 days is associated with lower recurrence and longer survival. In this study, we investigate the impact of outside referral and dental extractions on package time, with secondary detriment to relapse-free survival (RFS) and overall survival (OS).
METHODS: We conducted a retrospective chart review on patients with HNSCC who received primary surgical resection at an academic medical centre.
RESULTS: Ninety-four patients met eligibility criteria, 35% experienced recurrence, and 21% died. Median package time was 89.5 days, with 76% of patients achieving a package time ≤100 days. Receiving RT in-house was associated with a shorter package time (P = 0.0004) and higher completion rate within 100 days (P = 0.01). Dental extractions did not affect package time. A Kaplan-Meier analysis was performed to study survival, and a package time ≤100 days was not associated with a change in RFS or OS. A Cox proportional hazard model was used to investigate other factors hypothesized to impact patient survival; none had an effect on RFS, but cancer stage had an effect on OS (P = 0.01).
CONCLUSIONS: We identified that outside referrals, but not dental extractions, prolong treatment package times. We also saw no effect of package time on RFS or OS. These results suggest that patients requesting outside facility referrals for RT may benefit from a streamlined program that expedites the referral process.
Time-limited (12 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). LAKU family program (12 month program) includes 35 family-based meetings. Families are also given an opportunity to attend two separate family weekends. In addition to this, parent group format may include 10 meetings at maximum. A 24-month-program will include 15 additional family-based meetings.
Scars are classified into 5 types: Superficial scars, hypertrophic scars, atrophic scars, depressed scars, and keloid. These types are primarily characterized by abnormal production of fibroblasts and collagen, as well as the disorderly arrangement of connective tissue. Laser treatment for scars involves the coordinated activation of various signaling pathways and cytokines. However, the exact pathological mechanism for scar formation remains unclear, leading to a lack of radical treatment. Recently, laser treatment has gained popularity as a new minimally invasive approach for scar treatment. The emergence of new theories such as fractional, picosecond laser, and laser-assisted drug delivery has led to continuous advance in laser treatment. Up to now, it has been developed numerous novel treatments, including combined with drug, physical, and other treatments, which have shown superior therapeutic effects. In order to optimize laser treatment in the future, it is crucial to combine new materials with postoperative care. This will help clinicians develop more comprehensive treatment strategies. Therefore, it is important to explore treatment options that have broader applicability.
The invention discovers a Procambrus clarkii type i lysozyme gLysi2 gene for the first time, wherein the nucleotide sequence of the gLysi2 gene is SEQ ID NO. 1. The gene coding is utilized to prepare a gLysi2 protein, and the amino acid sequence of the gLysi2 protein is SEQ ID NO. 2. The invention also provides the application of the gene and the protein in the field of preventing and treating the white spot syndrome of prawns. The invention has effective antivirus function, extremely strong inhibiting and killing effect on the white spot syndrome baculovirus, and can effectively solve the problems of immunity and treatment of the white spot syndrome.
PURPOSE: To evaluate the expression of sry-box transcription factor 9 (SOX9) in orbital fibroblasts (OFs) of thyroid eye disease (TED) and to find its potential role and underlying mechanism in orbital fibrosis.
METHODS: OFs were cultured from orbital connective tissues obtained from patients with TED (n = 10) and healthy controls (n = 6). SOX9 was depleted by small interfering RNA or overexpressed through lentivirus transduction in OFs. Fibroblast contractile activity was measured by collagen gel contraction assay and proliferation was examined by EdU assay. Transcriptomic changes were assessed by RNA sequencing.
RESULTS: The mRNA and protein levels of SOX9 were significantly higher in OFs cultured from patients with TED than those from healthy controls. Extracellular matrix-related genes were down-regulated by SOX9 knockdown and up-regulated by SOX9 overexpression in TED-OFs. SOX9 knockdown significantly decrease the contraction and the antiapoptotic ability of OFs, whereas the overexpression of SOX9 increased the ability of transformation, migration, and proliferation of OFs. SOX9 knockdown suppressed the expression of phosphorylated ERK1/2, whereas its overexpression showed the opposite effect. Epidermal growth factor receptor (EGFR) is one of the notably down-regulated genes screened out by RNA sequencing. Chromatin immunoprecipitation-qPCR demonstrated SOX9 binding to the EGFR promoter.
CONCLUSIONS: A high expression of SOX9 was found in TED-OFs. SOX9 can activate OFs via MAPK/ERK1/2 signaling pathway, which in turn promotes proliferation and differentiation of OFs. EGFR was a downstream target gene of SOX9. SOX9/EGFR can be considered as therapeutic targets for the treatment of orbital fibrosis in TED.
Active plant principles are isolated by extracting Ammi visnaga seeds with water, mixing the resultant aqueous solution with a water-immiscible solvent in which the active principles are preferentially soluble, separating the aqueous and solvent phases, and recovering the active principles from the solvents.  Solvents specified are benzene, carbon tetrachloride, trichlorethylene and chloroform.  Complete evaporation yields a high-melting, waxlike residue consisting of khellin, visnagin, and a small proportion of unidentified highly-coloured contaminants, which may be defatted by the use of petroleum ether.  Partial evaporation, which produces a crystalline product practically free from contaminants, is preferably effected.  The aqueous phase after extraction of the p  desired principles is preferably returned to the process. Concentrations of khellin far in excess of its solubility in pure water are thus obtained, due possibly to the presence of an unidentified water-soluble solubilizing agent present in the Ammi visnaga seeds. Pure khellin may be isolated from khellin/visnagin mixtures by recrystallization from solution in an aliphatic alcohol containing from 4 to 8 carbons atoms, for example n-butycarbinol and less preferably amyl alcohol.  Using n-butylcarbinol as solvent, pure visnagin may be obtained from the mother liquor resulting from the recrystallization of the khellin by agitating with water and allowing the mixture to stand, preferably cooling with ice.
Measurements were made for conventional and independent at 1:1 proportion ventilation in supine position; then independent ventilation was discontinued and patient was moved to right or left decubitus position due to left or right lung surgery. Then were made measurements for conventional anaesthetic practices and followed independent at 1:1, 2:1, 3:1, 5:1 proportions ventilation routines. Constantly were monitored expired volume, peak respiratory pressure, dynamic compliance separately for each lung. Measurements covered also hemodynamic (MAP, HR) and oxygenation (SpO2). These attributes were documented at each point of the study. Subsequently, the control system was disconnected and performed typical anaesthetic procedures for thoracic surgery with a one-lung ventilation procedure.
Participants randomized to the Delayed Treatment arm will be placed on waitlist status and will not have any intervention from weeks 3 to 10. Participants will continue their usual care for their abdominal pain during this time. Then, this study arm will cross over to the guided imagery therapy mobile application intervention from weeks 11 to 18.
Hypertension is one of the most common chronic diseases in older people, and the prevalence is on the rise as the global population ages. Hypertension is closely associated with many adverse health outcomes, including cardiovascular disease, chronic kidney disease and mortality, which poses a substantial threat to global public health. Reasonable blood pressure (BP) management is very important for reducing the occurrence of adverse events. Frailty is an age-related geriatric syndrome, characterized by decreased physiological reserves of multiple organs and systems and increased sensitivity to stressors, which increases the risk of falls, hospitalization, fractures, and mortality in older people. With the aging of the global population and the important impact of frailty on clinical practice, frailty has attracted increasing attention in recent years. In older people, frailty and hypertension often coexist. Frailty has a negative impact on BP management and the prognosis of older hypertensive patients, while hypertension may increase the risk of frailty in older people. However, the causal relationship between frailty and hypertension remains unclear, and there is a paucity of research regarding the efficacious management of hypertension in frail elderly patients. The management of hypertension in frail elderly patients still faces significant challenges. The benefits of treatment, the optimal BP target, and the choice of antihypertensive drugs for older hypertensive patients with frailty remain subjects of ongoing debate. This review provides a brief overview of hypertension in frail older adults, especially for the management of BP in this population, which may help in offering valuable ideas for future research in this field.
The invention discloses a method for preparing granules for treating alcoholic cardiomyopathy arrhythmia. The granules are applied to the therapy of alcoholic cardiomyopathy. The method is characterized by comprising the steps of (1) distilling Litchi chinensis Sonn., Stachys kouyangensis(Van.) Dunn and Aeschynomene indica L. by water vapor, so as to extract volatile oil for later use, and enabling dregs to be standby; (2) crushing Gekko gecko Linnaeus and Setaria italica (L.) Beauv. into fine powder for later use; (3) uniformly mixing Selaginella tamariscina (Beauv.) Spring, Begonia handelii Irmsch., Poncirus tuifoliata (L.) Raf., Polygonum aviculare L., Magnolia amoena Cheng, Dracocephalum moldavica L., Callicarpa nudiflora Hook. Et Arn. and the dregs obtained in the step (1), carrying out ethanol extraction twice, merging two alcohol extracts, filtrating, recovering ethanol, and carrying out depressurized concentration, so as to form an extract; (4) adding the fine powder obtained in the step (2) into the extract obtained in the step (3), uniformly mixing, drying at the temperature of 60 DEG C, crushing into fine powder, adding polysorbate-80, granulating, drying, finishing, spraying the volatile oil obtained in the step (1), uniformly mixing, and packaging granules, thereby obtaining the granules. Proved by clinical trials, the granules have the characteristics of good treatment effect and relatively high safety in the therapy of alcoholic cardiomyopathy, so that the granules are worthy of clinical application and popularization.
The recommended dosage regimen of ZERBAXA in pediatric patients from birth to less than 18 years of age with cIAI and cUTI with an estimated glomerular filtration rate (eGFR) greater than 50 mL/min/1.73 m2 is described in Table 2. ZERBAXA is administered every 8 hours by intravenous infusion over 1 hour. The duration of treatment should be guided by the severity and site of infection and the patient’s clinical and bacteriological progress as shown in Table 2. For the treatment of cIAI, metronidazole should be given concurrently.

ZERBAXA is not recommended in pediatric patients who have an eGFR 50 mL/min/1.73m2 or less [see Use in Specific Populations (8.4)].

There is insufficient information to recommend a dosage regimen for pediatric patients with HABP/VABP [see Use in Specific Populations (8.4)].
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to wreak havoc worldwide, the "Cytokine Storm" (CS, also known as the inflammatory storm) or Cytokine Release Syndrome has reemerged in the public consciousness. CS is a significant contributor to the deterioration of infected individuals. Therefore, CS control is of great significance for the treatment of critically ill patients and the reduction of mortality rates. With the occurrence of variants, concerns regarding the efficacy of vaccines and antiviral drugs with a broad spectrum have grown. We should make an effort to modernize treatment strategies to address the challenges posed by mutations. Thus, in addition to the requirement for additional clinical data to monitor the long-term effects of vaccines and broad-spectrum antiviral drugs, we can use CS as an entry point and therapeutic target to alleviate the severity of the disease in patients. To effectively combat the mutation, new technologies for neutralizing or controlling CS must be developed. In recent years, nanotechnology has been widely applied in the biomedical field, opening up a plethora of opportunities for CS. Here, we put forward the view of cytokine storm as a therapeutic target can be used to treat critically ill patients by expounding the relationship between coronavirus disease 2019 (COVID-19) and CS and the mechanisms associated with CS. We pay special attention to the representative strategies of nanomaterials in current neutral and CS research, as well as their potential chemical design and principles. We hope that the nanostrategies described in this review provide attractive treatment options for severe and critical COVID-19 caused by CS.
Peanut allergy is a common ailment in the United States. Research suggests that the prevalence of peanut allergy in the United States has doubled over the last 5 years. Currently, the only effective treatment for peanut allergy is a peanut-free diet and quick access to self-injectable epinephrine in the event of peanut exposure. The sublingual route is a potential method to administer immunotherapy for the treatment of food allergies. The intent of this study is to induce desensitization and eventually tolerance to peanut protein and evaluate the safety and immunologic effects of daily sublingual immunotherapy (SLIT) for individuals with peanut allergy. The trial will enroll 40 participants. After the first 10 participants between the ages of 18 and 40 are enrolled, safety information will be reviewed. If there are no safety concerns, the study will continue to enroll the remaining participants between the ages of 12 and 40.

This clinical trial will last 172 to 216 weeks. Participants will be randomly assigned to receive peanut SLIT or placebo SLIT. All participants will have an entry oral food challenge (OFC). The treatment group will receive gradual dosing escalations of peanut SLIT and maintenance therapy over a 44-week period, followed by another OFC. Following the OFC, participants will be unblinded, and the placebo group will receive peanut SLIT escalated to a higher maximum dose than the first treatment group. Maintenance therapy will continue for both groups for more than 2 years.

Study visits will occur every 2 weeks during dosing escalations of peanut SLIT, followed by visits gradually spacing out during maintenance to every 12 weeks. At selected visits, a physical examination, skin prick tests, blood and urine collection, and atopic dermatitis and asthma evaluations will occur. Approximately 6 OFCs will be administered to each participant throughout the course of the study. Additionally, 10 participants will be enrolled as control participants who will not receive any study therapy and will only have blood drawn at 3 visits throughout the course of the trial.
Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, oral prednisolone on days 1-5, and filgrastim (G-CSF) subcutaneously (SC) on days 5-12. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
The polymeric medication consists of an inert synthetic carrier connected with a molecule having biological activity and a specific determinate with the use of amino acid or peptide spacers and this connection is allowed to contain the transversal bonds. The nested chains of the specified polymer can be created based on the connection using the transversal bonds. The polymeric units closed to N-(2-hydroxypropyl)- metakrylamide, 55 up to 99,7 molar percent are used as the polymeric carrier. Monosaccharide or oligosaccharide linked based on the amide bond to the peptide spacer is suitable to be used as the determinant. The polymeric medication can be prepared based on this principle, that N-(2-hydroxipropyl)metakrylamide co-polymerisation is done either with N-metakryloyl peptide or with p-nitrophenyl ester of that, while the final co-polymer is undertaken to the reaction with a reactive bio-active molecule, reactive determinant or the diamide nesting facility, while the ester or amide bonds are created. The advantage of this medication is a controlled intracellular unlocking in the ai
1448181 Phosphoric esters of cholestanol and epicholestanol LION DENTIFRICE CO Ltd 17 Dec 1974 [30 Jan 1974] 54499/74 Heading C2U [Also in Division A5] Phosporic esters of cholestanol and epicholestanol and their salts, are prepared from the parent ols by reaction with a phosphonylating agent in an inert solvent and hydrolysis or hydrogenolysis of the product. The epicholestanol derivatives are new. The reagents are defined as having the formula R 3 P#O wherein each R independently represents halogen, OH, lower alkoxy, haloalkoxy, cyanoalkoxy, amino, morpholino, imidazolyl, aryloxy or aralkyloxy, at least one being halogen or OH. The preferred reagent is POCl 3 . The hydrolysed product may be treated with an ion exchange resin. The ester may be converted to a salt before or after any ion exchange treatment. Named intermediates in the examples are 5α-cholestan- 3# - ol diphenylphosphate and phenylphosphate. The esters are stated to possess anti-inflammatory activity, and they may be made up into pharmaceutical compositions.
The intragastric balloon (IGB) is recognised as a minimally invasive intervention for the treatment of obesity. Here, we detail a rare and life-threatening complication stemming from this procedure. A female patient in her 40s, who had an IGB in situ for 14 months, presented at the emergency department with septic shock characterised by abdominal guarding and emesis. These symptoms were a direct result of IGB-induced bowel obstruction. We emphasise that the patient missed the recommended 6-month removal window, which in our opinion is the decisive cause leading to deflated balloon migration and subsequent complications. In the course of managing multiple critical events, the patient required multiple operations related to the bowel obstruction, numerous nutritional and psychological challenges. Currently, the patient is living with short bowel syndrome, secondary to the chronic intestinal failure, necessitating the administration of parenteral nutrition 6 days per week.
The dentifrice compositions comprise compositions which include detersive amounts of an oral surfactant and at least 1 % by weight of a benzoic acid salt or derivative thereof effective to remove plaque from dental surfaces. The combination of the foregoing active ingredients is particularly effective against plaque when used in the compositions of the present invention. The compositions of the present invention include a dentifrice carrier containing at least 1 % by weight of a benzoic acid salt and detersive amounts of an oral surfactant. In a preferred embodiment of the present invention, a toothpaste formulation is provided, which has, as one of its active ingredients, at least about 6 % by weight of a benzoic acid salt. The carrier is any paste, or gel or the like capable of being applied to a toothbrush and brushed onto the teeth. The powder compositions of this invention may be adapted for brushing application onto the teeth in the oral cavity or for use on dentures or other synthetic surfaces outside the oral cavity.
Patients will be asked apply a 40 mg/g creme containing 5-Fluorouracil once a day on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
PURPOSE: Provided is a composition of a herbal medicine using the grape as a main ingredient. The composition improves one's concentration and activates brain cells at the same time. Therefore, it restores health and improves one's concentration within a short period of time. CONSTITUTION: The composition of a herbal medicine for improving one's concentration is characterized by containing, based on the total weight of the composition, 90-95 wt.% of the grape juice. It further contains 3-5 wt.% of each of Angelicae Sinensis Radix, Longanae Arillus, Zizyphi Spinosi Semen, Atractylodis Rhizoma alba, Astragali Radix and ginseng, 2-3 wt.% of each of Angelicae Dahuricae Radix, Chrysanthemi Flos, Saussureae Radix, Aurantii Nobilis Pericarpium and Amomi Semen, 10-12 wt.% of each of Poria, Polygalae Radix, Acori Graminei Rhizoma and licorice root, 3 wt.% of ginger and 4 wt.% of Zizyphi Jujubae Fructus, based on 5-10 wt.% of the composition. The composition is formulated into decoction or powder.